Drugs / NNC9204-1706
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03661879 | Sep 2018 → Sep 2019 | metabolic disease, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC9204-1706 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03661879 ↗ |
| Route | Subcutaneous | “Participants will receive NNC9204-1706 subcutaneous (s.c., under the skin) injection(s) once daily (OD) for 10 weeks.” NCT03661879 ↗ |